araag2/HINT huggingface dataset:
Clinical trial NCT00287716 (phase 3, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: pirfenidone, placebo
SMILES: CC1=CN(C(=O)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Primary Inclusion criteria:

          -  diagnosis of idiopathic pulmonary fibrosis

          -  40 to 80 years of age

          -  Forced Vital Capacity greater than or equal to 50% predicted value

          -  Carbon monoxide diffusing capacity greater than or equal to 35% predicted value

          -  either Forced Vital Capacity or Carbon monoxide diffusing capacity less than or equal
             to 90% predicted value

          -  no improvement in past year

          -  able to walk 150 meters in 6 minutes and maintain saturation greater than or equal to
             83% while on no more than 6 liters per minute (L/min) supplemental oxygen

        Primary Exclusion criteria:

          -  unable to undergo pulmonary function testing

          -  evidence of significant obstructive lung disease or airway hyper-responsiveness

          -  in opinion of investigator patient is expected to need and be eligible for a lung
             transplant within 72 weeks after randomization

          -  active infection

          -  liver disease

          -  cancer or other medical condition likely to result in death within 2 years

          -  diabetes

          -  pregnancy or lactation

          -  substance abuse

          -  personal or family history of long QT (Q wave,T wave) syndrome

          -  other IPF treatment

          -  unable to take study medication

          -  withdrawal from other IPF trials
Clinical trial NCT00479388 (phase 3, status: completed)
Conditions: primary hypercholesterolemia, mixed dyslipidemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: comparator: simvastatin, niacin (+) laropiprant, comparator: atorvastatin calcium
SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC, CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 to 80 years of age with Primary hypercholesterolemia or mixed dyslipidemia

          -  Patients will be eligible for the study if their LDL-C values are within protocol
             specified range and meet other entry criteria

        Exclusion Criteria:

          -  Patient whose LDL-C values are not within protocol specified range
Clinical trial NCT01059539 (phase 3, status: completed)
Conditions: bipolar i disorder
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: cariprazine
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have provided informed consent prior to any study specific procedures.

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed
             by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (SCID).

          -  Patients who experienced a manic or mixed episode that required treatment within the
             past 12 months.

          -  Patients with normal physical examination, laboratory, vital signs, and
             electrocardiogram (ECG).

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I
             disorder.
Clinical trial NCT00329264 (phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.

          -  Be able to understand and comply with the requirements of the study.

          -  Able to understand and provide written informed consent

        Exclusion Criteria:

          -  Patients (female) must not be pregnant or lactating

          -  Current or past diagnosis of stroke or transient ischemic attack (TIA).
Clinical trial NCT00241488 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: rosuvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Visit 1:

               1. Written informed consent to participate in the trial (Appendix B)

               2. Male or female subjects, age > 18 years

               3. Primary hypercholesterolaemia with CV risk > 20%/10yrs, type 2 diabetes, a
                  history of CHD or other established atherosclerotic disease (definition given in
                  Appendix L).

               4. Subjects may be lipid-lowering therapy-naïve, but have completed 6-weeks dietary
                  counselling before this visit OR Subjects may be treated with the 'start' dose of
                  other lipid lowering therapy, which is ineffective, ie. The subject has not met
                  LDL-C treatment goals.

               5. Subjects willing to follow all study procedures including attendance at clinics
                  for scheduled study visits, fasting prior to blood draws and compliance with
                  study treatment regimen

                  Visit 2:

               6. Subjects switched from start dose of a lipid lowering therapy (commonly accepted
                  start dose) will have fasting LDL-C levels > 3.1 mmol (120 mg/dl)

               7. Newly treated subjects, after a six-weeks dietary counselling, will have fasting
                  LDL-C levels > 3.5 mmol/L (135 mg/dL)

               8. Fasting triglycerides £ 4.52 mmol/L (400 mg/dL)

               9. Switched patients must stop current lipid lowering treatment at randomisation
                  (Visit 2)

        Exclusion Criteria:

          1. Known heterozygous or homozygous familial hypercholesterolaemia or known type III
             hyperlipoproteinaemia (familial dysbetalipoproteinaemia)

          2. Documented secondary hypercholesterolaemia of any cause other than named in inclusion
             criteria 3

          3. History of serious adverse effect or hypersensitivity reactions to other HMG-CoA
             reductase inhibitors, in particular any history of myopathy

          4. Unstable angina within three months prior to inclusion in the study

          5. Active liver disease or hepatic dysfunction as defined by elevations of AST or ALT ³
             1.5 times the ULN. In this case, a second determination of hepatic tests will be
             performed after one week. If the dysfunction is confirmed, the subject must not be
             included in the study

          6. Known uncontrolled diabetes

          7. Uncontrolled hypertension defined as either resting diastolic blood pressure of >
             95mmHg or resting systolic blood pressure of > 200 mmHg

          8. Unexplained serum CK > 3 times ULN (eg not due to recent trauma, intramuscular
             injections, heavy exercise etc)

          9. Serum creatinine > 220 µmol/L (2.5mg/dL)
Clinical trial NCT00640562 (phase 3, status: completed)
Conditions: schizophrenia, depression
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: quetiapine extended release, risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective
             disorder according to DSM-IVTR

          -  Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and
             HAM-D item 1 score ≥2

        Exclusion Criteria:

          -  Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder

          -  Patients treated with depot antipsychotic medications within 1 dosing interval before
             day 0; patients treated with other AP oral medications during the trial except for the
             switch period

          -  Use of Clozapine within 28 days prior to enrollment or Clozapine non responders

          -  Any significant clinical disorder that, in the opinion of the investigator, made the
             subject unsuitable to be given treatment with an investigational drug

          -  An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter

          -  Patients who, in the opinion of the investigator, pose an imminent risk of suicide or
             a danger to self or others.
Clinical trial NCT01258920 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Met diagnostic criteria for schizophrenia according to DSM-IV-TR (disorganized type
             [295.10], catatonic type [295.20], paranoid type [295.30], residual type [295.60], or
             undifferentiated type [295.90]) for at least 1 year before screening. Prior medical
             records, written documentation or verbal information obtained from previous
             psychiatric providers obtained by the investigator must be consistent with the
             diagnosis of schizophrenia

          -  A PANSS total score of 60 to 120 at screening and baseline (Day 1)

          -  Documented history of exposure to either a risperidone formulation or a paliperidone
             formulation and known to be tolerated before baseline (Day 1). (Even if the patient's
             experience of taking risperidone or paliperidone cannot be confirmed at the time of
             informed consent, the patient will be able to meet this criterion if the patient takes
             oral risperidone 2 mg/day or more or paliperidone ER 6 mg/day or more for at least 4
             days between the day of informed consent and the day before baseline, and it is
             possible to confirm that there is no lack of tolerability in the patient)

          -  Women of childbearing potential must have a negative ß-human chorionic gonadotropin
             (ß-hCG) pregnancy test at the screening urine pregnancy test

          -  Patients must have signed an informed consent document indicating that they understand
             the purpose of and procedures required for the study and are willing to participate in
             the study.

        Exclusion Criteria:

          -  Primary active DSM-IV-TR Axis I diagnosis other than schizophrenia

          -  A DSM-IV-TR diagnosis of active substance dependence within 3 months before screening
             (nicotine and caffeine are not exclusionary)

          -  Relevant history of or current presence of any significant or unstable cardiovascular,
             respiratory, neurological (including seizures or significant cerebrovascular), renal,
             hepatic, hematologic, endocrine, immunologic, or other systemic disease

          -  History or current presence of neuroleptic malignant syndrome or tardive dyskinesia

          -  Known or suspected hypersensitivity or intolerance to risperidone, paliperidone, or
             any of their excipients (including egg yolks, soybean oil, phospholipids, and
             glycerol)
Clinical trial NCT00447278 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine, other standard therapy for adhd
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Inclusion criteria:

               -  6 to 16 years old

               -  Diagnosis of ADHD according to Diagnostic and Statistical Manual of Mental
                  Disorders Fourth Edition (DSM IV) confirmed by Kiddie Schedule for Affective
                  Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version
                  (SADS PL)

               -  Pharmacological naïve

               -  Normal intelligence as assessed by investigator

               -  Each patient (and/or legally authorized patient representative where required by
                  local law) must understand the nature of the study and must sign an Informed
                  Consent Document.

        Exclusion Criteria:

          -  Exclusion criteria

               -  History of bipolar disorder, any history of psychosis or autism spectrum disorder

               -  History of any seizure disorder

               -  Significant prior or current medical conditions

               -  History of alcohol or drug abuse within the past 3 months

               -  Patients who are taking concurrently any of the excluded medications in the
                  study.
Clinical trial NCT00443235 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: melphalan/prednisone/velcade, thalidomide/prednisone/velcade
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Must be able to comply with the protocol requirements.

          -  Must voluntary sign the informed consent before performance of any study-related
             procedure not part of normal medical care, with the understanding it can be withdrawn
             at any time without prejudice to future medical care.

          -  Age > 65 years.

          -  Patient recently diagnosed with symptomatic Multiple Myeloma based on standard
             criteria28 and that has not received any previous chemotherapy treatment for Multiple
             Myeloma Some steroid doses or bisphosphonates are allowed for emergencies before
             starting induction treatment.

          -  Patient has measurable disease, defined as follows:

        For secretory multiple myeloma, measurable disease is defined as any quantifiable serum
        monoclonal protein value and, where applicable, urine light-chain excretion of ≥ 200 mg/24
        hours.

          -  Patient has a ECOG performance status < 2

          -  Patient has a life-expectancy >3 months.

          -  Patient has the following laboratory values before beginning induction treatment:

        Platelet count ≥ 50000/mm3, hemoglobin ≥ 8 g/dl and absolute neutrophil count ≥ 1000/mm3.
        Lower values are allowed if they are due to marrow infiltration.

        Corrected serum calcium <14mg/dl. Aspartate transaminase (AST): ≤ 2.5 x the upper limit of
        normal. Alanine transaminase (ALT): ): ≤ 2.5 x the upper limit of normal. Total bilirubin:
        ≤1.5 x the upper limit of normal. Serum creatinine ≤ 2 mg/dl.

        Exclusion Criteria:

          -  Patients previously received treatment to Multiple Myeloma, except steroids doses for
             urgency or bisphosphonates.

          -  Non-secretor Myeloma

          -  Patients with < Grade 2 peripheral neuropathy within 14 days before enrolment.

          -  Patient had major surgery within 4 weeks before enrolment.

          -  Patient has hypersensitivity to bortezomib, boron or mannitol.

          -  Patient has received other investigational drugs within 30 days before enrolment.

          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV),
             Hepatitis B surface antigen-positive or active hepatitis C infection.

          -  Patient had a myocardial infarction within 6 months of enrollment or has New York
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities.

          -  Patient is enrolled in another clinical research study and/or is receiving an
             investigational agent for any reason.
Clinical trial NCT01076647 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes (diagnosed clinically) for at least 6 months

          -  Insulin naïve subjects (allowed are: previous short term insulin treatment up to 14
             days; treatment during hospitalisation or during gestational diabetes is allowed for
             periods longer than 14 days)

          -  Current treatment: metformin monotherapy or metformin in any combination with insulin
             secretagogues (sulphonylurea (SU) or glinide), DPP-4 inhibitor,
             alpha-glucosidase-inhibitor (acarbose) with unchanged dosing for at least 3 months
             prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination
             (including fixed combination) 1500 mg daily or maximum tolerated dose (at least 1000
             mg daily)-Insulin secretagogue (sulfonylurea (SU) or glinide): minimum half of the
             daily maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the
             daily maximal dose according to local labelling -alpha-glucosidase-inhibitor
             (acarbose): minimum half of the daily maximal dose or maximum tolerated dose

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  BMI (Body Mass Index) below or equal to 45.0 kg/m^2

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of: Thiazoledinediones (TZDs), Exenatide
             or Liraglutide

          -  Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous
             cell skin cancer)
Clinical trial NCT00150410 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: inhaled insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Currently treated and on a stable doses of drugs for the preceding two (2) months

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Smoking
Clinical trial NCT01662310 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone, placebo
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of schizophrenia according to Diagnostic and Statistical Manual of
             Mental Disorders, 4th Edition (DSM-IV)

          -  Have experienced an acute episode, with a Positive and Negative Syndrome Scale (PANSS)
             total score between 70 and 120 inclusive, at Screening and Baseline

          -  Women must be postmenopausal (for at least 1 year), surgically sterile (have had a
             hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of
             pregnancy), practicing a highly effective method of birth control, if sexually active

          -  Men must be using a highly effective method of birth control and must not donate sperm
             during the study and for 3 months after receiving the last dose of study drug

          -  Be willing and capable to complete the questionnaires and able to take oral
             medications independently

        Exclusion Criteria:

          -  Has drug dependence diagnosis according to DSM-IV (excluding nicotine and caffeine
             dependence) within 6 months before screening

          -  Participants with Crohn's disease and hepatic or renal diseases

          -  Has had relevant history of any significant and/or unstable cardiovascular,
             respiratory, neurologic (including seizures or significant cerebrovascular
             dysfunction), renal, hepatic, endocrine, or immunologic diseases

          -  Has had history of neuroleptic malignant syndrome (the disorder caused by
             antipsychotic drugs with symptoms of fever, muscle rigidity and delirium)

          -  Has had known or suspected Stevens Johnson Syndrome (an immune disease with symptoms
             of fever, sore throat, ulcers and conjunctivitis) after exposure to phenytoin,
             carbamazepine, barbiturates, or lamotrigine

          -  Had been treated with clozapine for treatment refractory or treatment resistant
             schizophrenia

          -  Has significant risk of suicide or homicidal behavior, or significant risk of
             deliberate self harm or harm to others

          -  Has taken isocarboxazid, phenelzine, selegiline and tranylcypromine within 4 weeks
             before screening

          -  Has received electroconvulsive therapy within 60 days before screening
Clinical trial NCT00386607 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren, valsartan, hydrochlorothiazide (hctz)
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria: -

          -  Male and female outpatients 18 years of age and older.

          -  For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥
             90 and < 110 mmHg at Visit 1 and Visit 4

          -  For previously treated patients with essential hypertension defined as msDBP ≥ 90 and
             < 110 mmHg after 2 to 4 weeks of washout (Visit 4)

          -  Patients who were eligible and able to participate in the study and who consented to
             do so after the purpose and nature of the investigation had been clearly explained to
             them (written informed consent).

        Exclusion Criteria:

          -  Severe hypertension (msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg)

          -  Women of child-bearing potential, unless they met definition of post-menopausal or
             were using acceptable methods of contraception.

          -  History or evidence of a secondary form of hypertension.

          -  History of hypertensive encephalopathy or cerebrovascular accident.

        Other protocol-defined inclusion/exclusion criteria may apply.